Acadia Pharmaceuticals Stock
Price
Target price
€22.93
€22.93
0.530%
0.12
0.530%
€27.38
13:16 / Tradegate
WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals gained 0.530% compared to yesterday.
The stock is one of the favorites of our community with 27 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is a slightly positive potential of 17.75% for Acadia Pharmaceuticals compared to the current price of 22.93 €.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 0.530% | 0.047% | 12.678% | 31.089% | 33.250% | 43.297% | -52.075% |
| Ironwood Pharmaceuticals | 0.640% | -5.455% | 95.000% | -6.587% | -25.714% | -73.099% | -68.163% |
| Novocure Ltd | -1.190% | -8.174% | -3.254% | -63.646% | -65.282% | -86.701% | -91.689% |
| Iovance Biotherapeutics Inc. | -1.320% | -10.811% | 19.228% | -77.316% | -72.705% | -70.951% | -94.691% |
Comments
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat